

1 **Title page**

2

3 **Title**

4 Long stability of SARS-CoV-2 RNA in dry and saliva swab samples stored for
5 diagnostics, Denmark

6

7 **Authors**

8 Alonzo Alfaro-Núñez^{1*}, Stephanie Crone², Shila Mortensen¹, Maiken Worsøe
9 Rosenstjerne¹, Anders Fomsgaard¹, Ellinor Marving¹, Sofie Holdflod Nielsen³,
10 Michelle Grace Pinto Jørgensen³, Arieh S. Cohen³ and Claus Nielsen¹

11

12 **Affiliations**

13

14 ¹ Department of Virus and Microbiological Special Diagnostics, Statens Serum
15 Institut, Artillerivej 5, 2300 Copenhagen S, Denmark

16

17 ² SSI Diagnostica, Herredsvejen 2, 3400 Hillerød, Denmark

18

19 ³ TestCenter Danmark, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S,
20 Denmark

21

22 * **Correspondence:** alonzoalfaro@gmail.com, alnz@ssi.dk

23

24 **Abstract**

25

26 During the current COVID-19 pandemic, Danish authorities demand that clinical
27 swab samples must be analysed within 72 hours. This time constraint was adopted
28 to guarantee a quick and efficient response. As today, analysis results are given
29 within 20 hours average fulfilling this demand. However, it is unclear for how long
30 and under which conditions swab specimens can be stored without clinically
31 affecting SARS-CoV-2 RNA stability. This study demonstrates that swabs specimens
32 can be stored at -20°C and +4°C for up to 26 days without affecting RT-qPCR
33 results. However, early detection of asymptomatic cases is important to reduce
34 spreading COVID-19 may be the final consequence not only in Denmark but
35 worldwide.

36

37 **Keywords**

38

39 Viral survival, COVID-19, surveillance, clinical samples, oropharyngeal, saliva, RNA
40 quantification methods

40

41 **Rapid increase of SARS-CoV-2 clinical sampling**

42

43 As the number of cases of COVID-19, severe acute respiratory syndrome
44 Coronavirus 2 (SARS-CoV-2), keep rapidly increasing during the current pandemic,
45 there are no signs of the disease slowing down during a the second or even third
46 wave of infection. As such, numbers of clinical samples for detection of SARS-CoV-2
47 continue to grow worldwide (<https://www.ecdc.europa.eu/en/covid-19/data> and
48 <https://www.cdc.gov/coronavirus/2019-ncov/index.html>). The increasing number of
49 samples put pressure on logistics at the various test laboratories and challenges
50 their ability to analyse samples in a timely fashion. While new, innovative and faster

51 methods for screening and diagnosing patients are constantly being developed (e.g.
52 CRISPR-Cas based, and other isothermal amplification methods, conventional
53 antigen-based test for viral proteins, PCR assays for detecting viral amplicons),
54 extraction of nuclei acids, followed by either reverse transcription polymerase chain-
55 reaction (RT-PCR) or real-time RT-PCR (RT-qPCR) approaches, remain the most
56 commonly used due to their high sensitivity and relatively low cost (1).

57

58 Healthcare institutions, research labs and governments have made great efforts to
59 maintain the flow of analytical diagnostics on time to provide results for the adequate
60 detection of positive SARS-CoV-2 clinical cases worldwide.

61

62 In Denmark, there are two different test tracks available. Hospitals across the
63 country run the health test track and are responsible for testing people with clear
64 COVID-19 symptoms. While Test Centre Denmark (TCDK) at the Statens Serum
65 Institut (SSI) runs the society test track (STT), which allows asymptomatic persons,
66 or people with only mild symptoms, or even people who just wants to know their
67 health status to be tested. One of the main premises while establishing TCDK during
68 the early 2020 was that machines, consumables and reagents used at this facility,
69 must not be the same as the ones used at the health track, to avoid the shortage
70 experienced during the early stages of the pandemic across all Europe, and
71 worldwide. Up today, TCDK runs in average more than 100,000 COVID-19 tests a
72 day as the government recommends every person going physically to work to be
73 tested at least once a week.

74

75 Additionally, the established procedure by SSI requires and demands that all
76 COVID-19 clinical swabs have to be analysed within 72 hours after sample
77 collection. In fact, over 90% of the samples are analysed and results are given within
78 20 hours average. Any sample received and analysed after this time limit is reported
79 as inconclusive and then discarded. The rationale for the 72-hour deadline is based
80 on two principals. The first principal is that for a testing strategy to be effective
81 results must be available as soon as possible. As the final results represent a
82 moment in time, a delayed outcome may no longer signify the actual health status of
83 a patient. Moreover, persons with even slight symptoms are expected to self-
84 quarantine while waiting for the results and this is a substantial burden. The second
85 principal is that when large scale testing was started, it was unknown how long
86 SARS-CoV-2 RNA remains stable on clinical sample swabs. A stability below 72
87 hours was considered reasonable (2). Furthermore, the laboratories for the STT are
88 now centralized within two facilities across the country, samples are received from all
89 over the nation and may be delayed in transport, which will subsequently cause them
90 to be excluded from screening diagnostic if arrive outside this time threshold. This
91 may represent a loss of potential COVID-19 positive cases carrying any of the
92 different SARS-CoV-2 variants (3), and raises the question to how long does SARS-
93 CoV-2 RNA remain stable in the clinical swab samples during transportation and
94 before arrival to the respective analytical centre?

95

96 Despite the large volume of documentation generated in 2020 about the
97 pathogenicity, infectivity and detection of SARS-CoV-2 and COVID-19, there is,
98 however, only a handful of studies evaluating the longevity and conditions for SARS-
99 CoV-2 RNA particle stability maintenance in clinical swabs samples for
100 transportation in different medias (4-6). Furthermore, to our knowledge, there is no

101 available data on the stability of SARS-CoV-2 RNA during transportation and
102 longevity in dry swabs (without any preservation buffer). Therefore, in our current
103 study, we add to the previous findings on viral survival and detection in order to
104 assess the stability at different environmental temperatures of SARS-CoV-2 RNA
105 particles in swab material without the addition of a preservation media.

107 **Experimental design for viral quantification**

109 A total of 120 swabs (CLASSIQSwabs™ Dry Swabs, COPAN) were spiked with
110 SARS-CoV-2 in the lab under two main conditions, 60 swabs in “Dry” by adding 5 µL
111 of the virus directly to the tip of the swab, and 60 oropharyngeal swabs in “Saliva”
112 solution sampled from one unique person, and then, by also adding 5 µL of SARS-
113 CoV-2. No transport or stabilizing media was added in either of the two conditions,
114 thus, both should be considered dry swabs. Swab samples were stored at three
115 different temperatures (-20°C, +4°C and +20°C), and thereafter analysed in triplicate
116 by RT-qPCR after 1, 3, 5, 8, 9, 15 and 26 days. All incubations took place in dark to
117 overrule the potential effect of light UV radiation in the degradation of RNA
118 molecules.

119
120 A well-characterized strain of SARS-CoV-2 (2019-nCoV/Munchen 1-2-2020/964,
121 Charite/Berlin) diluted in PBS, was used to spike the swabs with a C_T -value of 29,4
122 ($\sim 10^3$ viral copies/ µL). Dilution series of the original standard sample (C_T -value of
123 20; $\sim 10^6$ viral copies/ µL) allowed the estimation of RNA viral copies/µL.

125 Samples were analysed at TCDK where 700 µL of PBS were added to the swabs,
126 and the samples were left agitating on a shaker for 10 min (700RPM). Total nucleic
127 acids were extracted from 200 µL of sample using a Biomek i7 (Beckman Coulter)
128 and the RNAdvance Blood kit (Beckman Coulter) following the manufacturer
129 guidelines and eluting in 50 µL DNase and RNase free water. RT-qPCR was
130 performed on a CFX96 (Bio-Rad) using 5 µL elute in a total reaction volume of 25
131 µL. The PCR reaction contains Luna Probe One-Step React Mix (New England
132 Biolabs), 0,3% IGEPAL CA-630. The Primers & Probes targeting the E-gene region
133 and Cycling conditions as described in Corman *et al.* 2020 (7). This standard set up
134 for analysing all the SST swab samples keeps being updated and improved day by
135 day.

137 **How long does SARS-CoV-2 survive in oropharyngeal dry swab clinical 138 samples?**

140 The design of our study differed from previous investigations that compared swab
141 types and specimen collection methods within a clinical setting (4,8). Despite the fact
142 that nasopharyngeal swabs are considered to reach the highest-yield for diagnostic
143 testing of SARS-CoV-2, oropharyngeal swabs and saliva are also broadly used (9).
144 Studies suggest that saliva may be a suitable and high-yield diagnostic type of
145 sample for detection of SARS-CoV-2. According to local viral replication, in addition
146 to the potential mixing in saliva of lower and upper respiratory tract fluids that can
147 carry virus (9,10). Our approach was laboratory based and no patients were
148 involved. The analysis was only designed as a development study, using the current
149 oropharyngeal national swab method, to provide insight into the stability of RNA viral
150 particles in dry and saliva swabs and not in the disease itself. Even though C_T values

151 provide quantitative information over time, issues such as the relationship between
152 viral load and disease severity could therefore not be assessed and were never the
153 target of the current assay.

154

155 In overall, no significant variation was observed in the C_T values (and viral copy
156 number/ μL) over time within the two main conditions (see Fig. 1), except for the
157 saliva treatment at $+20^\circ\text{C}$ which after 9 days experienced an increase in the mean
158 C_T values (from $\sim 10^3$ to $\sim 10^1$ viral copies / μL concentration decrease). A direct
159 correlation of higher viral stability in lower temperatures over time for both main
160 conditions was observed (Table 1). Moreover, there was also a slight tendency of
161 saliva swab samples to give lower C_T values and thus, to be a more stable
162 environment for the survival of SARS-CoV-2 RNA during the first 9 days of
163 incubation. A study showed that SARS-CoV-2 could be detected using RT-qPCR on
164 swabs after 21 days at room temperature (8). In another study, absolute dry swabs
165 taken from clinical patients showed a slight reduction in utility for several respiratory
166 viruses, supporting our results (2). Although, both conditions in our study should be
167 essentially considered as dry swabs as no preservation buffer were added. The
168 saliva swabs represented better the actual enzymatic environment found in real
169 clinical swab samples, than the absolute dry swabs, in which only 5 μL of the virus
170 was added directly to the tip of the swab. Nevertheless, to our knowledge there is no
171 study evaluating the direct effect of oropharyngeal enzymes in the stability of SARS-
172 CoV-2 and thus, we cannot further conclude.

173

174 As mentioned above, temperature was observed to play a significant role in
175 stabilizing the RNA molecules of the virus, in particular for the saliva swabs when
176 compared to the dry swabs (Suppl. Mat. 1). Using linear regression, there was a
177 statistically significant difference in C_T in the saliva swabs after 3 days ($P = 0,003$),
178 15 days ($P = 0,003$) and 26 days ($P = 0,03$) of incubation, and in dry swabs after 8
179 days ($P = 0,004$) incubation in between -20°C and ambient room temperature
180 (20°C). Moreover, a significant difference was also noticed for the saliva after 15
181 days ($P = 0,006$) when compared the $+4^\circ\text{C}$ and $+20^\circ\text{C}$ temperatures, and in the dry
182 treatment after 8 days ($P = 0,03$) in between the -20°C and $+4^\circ\text{C}$ incubation
183 temperature (Table1). Finally, samples at -20°C were slightly more stable than $+4^\circ\text{C}$
184 and samples at $+20^\circ\text{C}$ showed increase in viral particles degradation with lower viral
185 copies (Suppl. Mat. 2).

186

187 There are several available protocols and regulations for oropharyngeal swab
188 samples collection and the different media available for transportation (11,12).
189 Oropharyngeal swabs are among the most used type of clinical sample specimens
190 collected in combination with nasopharyngeal swabs during the current pandemic
191 (6). In Denmark, hospitals with the health track use different kinds of transport buffer
192 containing a hydrolysing agent to the swabs right after collection. However, SSI with
193 the STT does not add a transport buffer and swab samples are stored dry after
194 collection until they reach TCDK for nuclei acid extraction and RT-qPCR analysis.
195 There is evidence supporting that transporting dry swabs do not compromise RNA
196 recovery from clinical samples (2). Our results confirm that the current method
197 selected for the STT do not compromise and retain SARS-CoV-2 RNA up to 26 days
198 (a highly surprising number of days) without a significant variation or reduction in C_T -
199 values if the samples are kept cold. As such, implementing the use of dry swabs
200 represents also an economical value by reducing the cost of additional preservation

201 buffers. Furthermore, the swabs used by TCDK were selected based on a
202 preliminary assay that quantified the retention of viral particles by comparing different
203 types of swab materials (Suppl. Mat. 3).

204

205 Denmark has become a worldwide reference for developing performance in
206 detection of COVID-19 (8). Testing delays and laboratory bottlenecks have
207 contributed to the aggravation spread of COVID-19 infections. Therefore, an
208 important aspect to take into consideration supporting the innovative implementation
209 of STT is the reduction of spreading COVID-19 by the early detection of
210 asymptomatic cases.

211

212 As such, to have a good knowledge of stability survival of SARS-CoV-2 RNA in dry
213 swabs can serve as reference guideline and important for planning during the current
214 pandemic and future events.

215

216 This study demonstrates that swabs specimens can be stored at -20°C and +4°C for
217 up to 26 days without clinically affecting RT-qPCR results.

218

219 **Ethical statement**

220 Exemption for review by the ethical committee system and informed consent was
221 given by the Committee on Biomedical Research Ethics - Capital region in
222 accordance with Danish law on assay development projects (see Journal-nr.: H-
223 21000338).

224 **Acknowledgements**

225

226 We would like to extend our gratitude to Susanne Lopez Rasmussen and Bettina
227 Andersen for their technical assistance.

228

229 **Author contributions**

230

231 Alonzo Alfaró-Núñez (AAN): conceptualization, writing original draft, analysis and
232 validation, approved final MS

233 Stephanie Crone (SC): review and edit, statistical analysis, approved final MS

234 Sofie Holdflod Nielsen (SHN), Michelle Jørgensen (MJ): generation of data,
235 approved final MS

236 Shila Mortensen (SM), Arie S. Cohen (ASC) and Claus Nielsen (CN):
237 conceptualization, review and edit, approved final MS

238 Maiken Worsøe Rosenstjerne (MWR), Anders Fomsgaard (AF) and Ellinor Marving
239 (EM): review and edit, approved final MS

240

241 **Competing interests**

242 The authors declare no competing interests.

243

244 **References**

245

246 1. D'Cruz RJ, Currier AW, Sampson VB. Laboratory Testing Methods for Novel
247 Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Front Cell

- 248 Dev Biol. Frontiers; **2020**; 8.
- 249 2. Moore C, Corden S, Sinha J, Jones R. Dry cotton or flocked respiratory swabs
250 as a simple collection technique for the molecular detection of respiratory
251 viruses using real-time NASBA. Journal of Virological Methods. Elsevier; **2008**;
252 153(2):84–89.
- 253 3. Spiess K, Alfaro-Núñez A, Marving E, et al. *Development of RT-PCR to detect*
254 *the multigeographical variants in the SARS-CoV-2 spike glycoprotein gene*. In
255 preparation.
- 256 4. Rogers AA, Baumann RE, Borillo GA, et al. Evaluation of Transport Media and
257 Specimen Transport Conditions for the Detection of SARS-CoV-2 by Use of
258 Real-Time Reverse Transcription-PCR. McAdam AJ, editor. J Clin Microbiol.
259 American Society for Microbiology Journals; **2020**; 58(8):1564.
- 260 5. Ren S-Y, Wang W-B, Hao Y-G, et al. Stability and infectivity of coronaviruses
261 in inanimate environments. WJCC. **2020**; 8(8):1391–1399.
- 262 6. Perchetti GA, Huang M-L, Peddu V, Jerome KR, Greninger AL, McAdam AJ.
263 Stability of SARS-CoV-2 in Phosphate-Buffered Saline for Molecular Detection.
264 McAdam AJ, editor. J Clin Microbiol. American Society for Microbiology
265 Journals; **2020**; 58(8).
- 266 7. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus
267 (2019-nCoV) by real-time RT-PCR. Eurosurveillance. European Centre for
268 Disease Prevention and Control; **2020**; 25(3):2000045.
- 269 8. Skalina KA, Goldstein DY, Sulail J, et al. Extended storage of SARS-CoV-2
270 nasopharyngeal swabs does not negatively impact results of molecular-based
271 testing across three clinical platforms. Journal of Clinical Pathology. BMJ
272 Publishing Group; **2020**.
- 273 9. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of
274 Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular
275 Detection: A Systematic Review and Meta-analysis. J Clin Microbiol. **2021**.
- 276 10. Chen L, Zhao J, Peng J, et al. Detection of SARS-CoV-2 in saliva and
277 characterization of oral symptoms in COVID-19 patients. Cell Prolif. John
278 Wiley & Sons, Ltd; **2020**; 53(12):1539.
- 279 11. Druce J, Garcia K, Tran T, Papadakis G, Birch C. Evaluation of Swabs,
280 Transport Media, and Specimen Transport Conditions for Optimal Detection of
281 Viruses by PCR. J Clin Microbiol. 5 ed. American Society for Microbiology
282 Journals; **2012**; 50(3):1064–1065.
- 283 12. Rodino KG, Espy MJ, Buckwalter SP, et al. Evaluation of Saline, Phosphate-
284 Buffered Saline, and Minimum Essential Medium as Potential Alternatives to
285 Viral Transport Media for SARS-CoV-2 Testing. McAdam AJ, editor. J Clin
286 Microbiol. American Society for Microbiology Journals; **2020**; 58(6).

288 **Table, Figure and Supplemental materials legends:**

289 **Table 1.** Statistical comparison of C_T values per conditions. C_T mean value results
290 with the SD (standard deviation) values for the two main conditions, in "saliva"
291 medium and in dry (no medium). Swabs were spiked with 5 μ L of SARS-CoV-2
292 cultivated virus and quantified after 1, 3, 5, 8, 9, 15 and 26 days.
293 Simultaneously, for each treatment, three different environmental temperature
294 were evaluated (-20°C, 4°C and +20°C). Moreover, three replicas were
295 quantified within each treatment in addition to a negative control. Finally, no
296 transport or stabilizing media was added to neither of the two conditions, thus,
297 both should be considered dry swabs.



298 **Figure 1.** C_T values variation and RNA viral copies / μ L concentrations in dry and
299 saliva swabs over time. RNA viral copies / μ L mean concentrations over time
300 are presented in panels **A** for saliva swabs and panel **B** for dry swabs. C_T value
301 mean results for the two main categories, in panel **C** for saliva medium and
302 panel **D** for absolutely dry. Swabs were spiked with 5 μ L of SARS-CoV-2
303 cultivated virus and quantified after 1, 3, 5, 8, 9, 15 and 26 days. Simultaneously
304 and for each treatment, three different environmental temperature were
305 evaluated at -20°C, 4°C and +20°C. Three (3) replicas were quantified within
306 each treatment in addition to a negative control. No transport or stabilizing
307 media was added to neither of the two conditions, thus, both should be
308 considered dry swabs.

309 **Supplemental Material 1.** Statistical analysis of C_T values.



310 **Supplemental Material 2.** Standard curve RNA viral copies / μ L concentrations.

311 **Supplemental Material 3.** Detection of SARS-CoV-2 using three commercial swab
312 types quantifying the swab retention performance.

Viral copies/ μl



Ct values



SARS-CoV-2 in saliva medium							
Mean CT (SD) on day:							
	1	3	5	8	9	15	26
-20°C	31,4 (0,7)	32,3 (1,1)	30,8 (0,4)	32,2 (0,9)	31,6 (1,4)	31,8 (0,4)	31,5 (0,5)
4°C	30,9 (1,3)	31,1 (0,3)	30,9 (1,3)	31,0 (0,1)	31,2 (0,3)	32,0 (0,6)	32,0 (0,06)
20°C	30,8 (0,5)	29,5 (1,7)	31,8 (2,1)	30,7 (0,7)	31,3 (0,8)	34,6 (0,3)	33,4 (1,0)
P values day:							
	1	3	5	8	9	15	26
-20°C vs. 4°C	0,76	0,32	1	0,38	0,91	0,96	0,79
-20°C vs. 20°C	0,73	0,003	0,43	0,14	0,93	0,003	0,05
4°C vs. 20°C	1,00	0,11	0,49	0,92	1,00	0,006	0,21
P values day 1 vs day 9				P values day 1 vs day 26			
-20°C	1,00			1,00			
4°C	1,00			0,73			
20°C	1,00			0,03			

SARS-CoV-2 no medium dry swab							
Mean CT (SD) on day:							
	1	3	5	8	9	15	26
-20°C	31,8 (0,6)	31,9 (0,8)	31,8 (2,0)	31,1 (0,4)	31,8 (0,48)	31,2 (1,4)	31,9 (0,3)
4°C	33,3 (0,4)	32,8 (2,0)	31,6 (0,4)	33,2 (0,4)	32,7 (0,5)	31,2 (1,6)	32,1 (1,3)
20°C	32,4 (0,8)	33,8 (0,3)	32,7 (1,3)	34,0 (1,7)	33,1 (0,7)	32,5 (0,5)	33,2 (0,6)
P values day:							
	1	3	5	8	9	15	26
-20°C vs. 4°C	0,21	0,51	0,96	0,04	0,63	1,00	0,99
-20°C vs. 20°C	0,77	0,08	0,54	0,004	0,34	0,33	0,32
4°C vs. 20°C	0,55	0,51	0,38	0,67	0,85	0,32	0,41
P values day 1 vs day 9				P values day 1 vs day 26			
-20°C	1,00			1,00			
4°C	0,99			0,77			
20°C	0,98			0,97			